We overexpressed NKX3.1 in LNCaP cells and examined its effects compared to control cells under treatments to mimic common therapeutic strategies employed in the clinic: growth in phenol-red free media containing charcoal stripped serum (CSS), which is utilized to model the use of ADT therapy in treating PCa, and treatment with either physiological levels of androgens (1 nM R1881 [30]) or AR- ntagonization (20 μM enzalutamide [8]). This evidence concerns the gene NKX3-1 and posterior cortical atrophy.